Coming off weight loss injections: what actually happens, and when it might be right

What trials tell us about stopping treatment

The clearest evidence comes from the extension and withdrawal arms of the major phase-3 trials. In the STEP 1 trial, published in the New England Journal of Medicine, participants who stopped semaglutide after 68 weeks regained roughly two-thirds of the weight they had lost within the following year. The pattern for tirzepatide is similar. This is not a failure of willpower, it reflects how these medicines work. GLP-1 and dual GIP/GLP-1 receptor agonists reduce appetite signals and slow gastric emptying while they are active in the body. When treatment stops, those effects wind down, and hunger gradually returns to something closer to its original level.

Understanding this helps reframe a common misconception worth naming: many people assume the weight loss achieved on treatment is 'locked in' once they stop. The data suggest otherwise for most people, which is why trial researchers and UK clinicians treat duration of treatment as a meaningful clinical variable, not a formality. If you are curious about the broader question of what happens when you come off weight loss injections in practical terms, that page covers the physiological timeline in more detail.

Why the body responds the way it does after stopping

These medicines act on receptors in the gut, pancreas and brain that regulate appetite, fullness and blood-sugar balance. Their effects are sustained only while the drug concentration is maintained. Once you stop injecting, plasma levels fall over one to two weeks (the half-lives of semaglutide and tirzepatide mean they clear slowly rather than abruptly, so there is rarely a sudden hunger surge on day one). Over the following weeks, though, appetite regulation drifts back toward baseline.

The NHS's guidance on tirzepatide notes that treatment is intended to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone intervention. That context matters here: patients who have used the appetite-reduced period to build consistent eating habits tend to fare better after stopping than those who found the lifestyle component difficult. None of this is a guarantee; individual responses vary widely. The side effects of coming off weight loss injections page covers what to watch for in the first few weeks specifically.

When stopping might be the right decision, and how to approach it

There are legitimate reasons to stop: achieving a goal weight and wanting to test maintenance, managing a pregnancy or planned conception (these medicines are not recommended in pregnancy), experiencing side effects that outweigh the benefits, or simply reaching the point where a prescriber and patient agree treatment has run its course. NICE's appraisal of tirzepatide (TA1026) includes a review point if weight loss is less than five per cent after six months at the highest tolerated dose, which gives a sense of how clinicians think about the cost-benefit calculation over time.

If stopping is the plan, a gradual, supervised exit tends to be better than an abrupt one. That means your prescriber should know, rather than you simply not reordering. They can help you think about timing, what to monitor, and whether any other support (dietary counselling, for example) is worth arranging before treatment ends. For context on what private treatment involves and how clinicians think about the cost of continuing versus stopping, the weight loss treatment overview sets out the full picture.

Maintenance: what the realistic options look like

A smaller group of people do successfully keep most of their weight off after stopping, and understanding what distinguishes them is useful. Published data and clinical experience point to a few consistent factors: a longer duration of treatment (giving more time for habit formation), a meaningful reduction in starting BMI, and active engagement with diet and activity during treatment rather than relying on the medicine alone. None of these factors predicts individual outcomes with certainty, but they give a framework for an honest conversation with your prescriber.

For those who stop and then experience significant regain, restarting treatment is a conversation worth having. There is no clinical rule against it, provided the prescriber is satisfied that suitability criteria are still met. The decision about whether (or when) to restart sits with your clinical team, and a fresh assessment would normally be part of that process. If you are weighing up the options and want to understand which medicine tends to produce results most rapidly, our page on which injection works quickest for weight loss compares the clinical data in more detail. It is also worth knowing that people sometimes encounter off-brand versions of these injections, and that page explains what the safety and regulatory concerns are if you come across them. If you want to know more about the medicines themselves, the weight loss injections overview and the conditions for safely coming off treatment are good starting points. Our clinical team's approach to these decisions is outlined on the clinical team page.

If you are thinking about your next step (whether that is planning a supervised exit, restarting, or simply understanding your options) speaking to our prescribers is a good place to start. A consultation is free, and a named GPhC-registered clinician reviews every submission the same day.